ArticleBMC cancer2026
Tumor volume change rate based on three-dimensional reconstruction as a predictor of pathological response and survival prognosis in esophageal squamous cell carcinoma with neoadjuvant immunochemotherapy.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThis research aimed to explore the significance of tumor volume change rate (TVCR) in predicting pathological response and survival prognosis for esophageal squamous cell carcinoma receiving neoadjuvant immunochemotherapy.
methodsEsophageal squamous cell carcinoma patients receiving neoadjuvant immunochemotherapy followed by esophagectomy between October 2020 and March 2024 were reviewed. The TVCR was measured and calculated through three-dimensional reconstruction based on computed tomography images. Pathological response, operative characteristics, postoperative complications were compared between the group with TVCR ≤ 45% and the group with TVCR > 45% using chi-square test or independent sample t-test. The receiver operating characteristic curve and area under the curve (AUC) were employed to determine the efficacy of TVCR in predicting pathological response. The overall survival (OS) and disease-free survival (DFS) were estimated using the Kaplan-Meier method with log-rank test. The univariate and multivariate Cox regression models were performed to identify the independent prognostic factors.
resultsA total of 120 esophageal squamous cell carcinoma patients receiving neoadjuvant immunochemotherapy were enrolled. The group with TVCR > 45% had significantly more cases achieving major pathological response (MPR) compared to the group with TVCR ≤ 45% (49.2% vs. 27.3%, P = 0.014). The TVCR outperformed Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) criteria in predicting MPR (AUC, 0.614 vs. 0.574). Patients with TVCR > 45% had better 3-year OS (88.7% vs. 60.7%, P < 0.001) and DFS rates (76.8% vs. 49.8%, P < 0.001) compared to those with TVCR ≤ 45%. Additionally, TVCR was determined as an independent prognostic factor for OS and DFS in esophageal squamous cell carcinoma receiving neoadjuvant immunochemotherapy.
conclusionsThe TVCR can serve as a predictor for pathological response and survival prognosis in esophageal squamous cell carcinoma treated with neoadjuvant immunochemotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.